Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy
Document Type
Article
Publication Date
12-1-2015
Publication Title
Photodiagnosis and Photodynamic Therapy
Department
Thayer School of Engineering
Abstract
: Although aminolevulinic acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT)is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment. This study examined the feasibility of using pre-treatment measurements of PpIX concentration in AK lesions to predict response of ALA-PpIX PDT. Methods: A non-invasive fiber-optic fluorescence spectroscopy system was used to measure PpIX concentration in patients undergoing standard-of-care ALA-PDT for AK. All patients provided assessments of pain at the time of treatment (n = 70), and a subset reported pain and erythema 48–76 h after treatment (n = 13).
DOI
10.1016/j.pdpdt.2015.10.006
Dartmouth Digital Commons Citation
Kanick, Stephen; Davis, Scott; Sheehan, KL; Zhao, Yan; Hasan, Tayyaba; Maytin, Edward; Pogue, Brian; and Chapman, Michael, "Pre-treatment protoporphyrin IX concentration in actinic keratosis lesions may be a predictive biomarker of response to aminolevulinic-acid based photodynamic therapy" (2015). Dartmouth Scholarship. 87.
https://digitalcommons.dartmouth.edu/facoa/87
